135 related articles for article (PubMed ID: 32703006)
1. Bcl-2, p53, and Ki-67 expression in pterygium and normal conjunctiva and their relationship with pterygium recurrence.
Turan M; Turan G
Eur J Ophthalmol; 2020 Nov; 30(6):1232-1237. PubMed ID: 32703006
[TBL] [Abstract][Full Text] [Related]
2. The role of cyclin D1, BCL-2, p53 and Ki-67 in epithelial cells in the etiopathogenesis of pterygium.
Süren E; Nergiz D; Bilgin B; Çoban DT; Akgündüz Z; Sadullahoğlu C; Süren D
Indian J Pathol Microbiol; 2021; 64(2):238-242. PubMed ID: 33851614
[TBL] [Abstract][Full Text] [Related]
3. Expression of cell proliferation and apoptosis biomarkers in pterygia and normal conjunctiva.
Liang K; Jiang Z; Ding BQ; Cheng P; Huang DK; Tao LM
Mol Vis; 2011; 17():1687-93. PubMed ID: 21738398
[TBL] [Abstract][Full Text] [Related]
4. The expression and significance of p53 protein and Ki-67 protein in pterygium.
Ljubojević V; Gajanin R; Amidzić L; Vujković Z
Vojnosanit Pregl; 2016 Jan; 73(1):16-20. PubMed ID: 26964379
[TBL] [Abstract][Full Text] [Related]
5. Expression of p53 and Ki-67 proteins in patients with increasing severity and duration of pterygium.
Mahesh M; Mittal SK; Kishore S; Singh A; Gupta N; Rana R
Indian J Ophthalmol; 2021 Apr; 69(4):847-850. PubMed ID: 33727444
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of vascular endothelial growth factor (VEGF) and p53 expression in pterygium from Tunisian patients.
Khalfaoui T; Mkannez G; Colin D; Imen A; Zbiba W; Errais K; Anane R; Beltaief O; Zhioua R; Ben Hamida J; Lizard G; Ouertani-Meddeb A
Pathol Biol (Paris); 2011 Jun; 59(3):137-41. PubMed ID: 19481369
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of fractalkine and its histopathological characteristics in primary pterygium.
Turan M; Turan G
Graefes Arch Clin Exp Ophthalmol; 2019 Dec; 257(12):2743-2750. PubMed ID: 31637486
[TBL] [Abstract][Full Text] [Related]
9. Association of Ki-67, p53, and bcl-2 expression of the primary non-small-cell lung cancer lesion with brain metastatic lesion.
Bubb RS; Komaki R; Hachiya T; Milas I; Ro JY; Langford L; Sawaya R; Putnam JB; Allen P; Cox JD; McDonnell TJ; Brock W; Hong WK; Roth JA; Milas L
Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1216-24. PubMed ID: 12128123
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
11. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
[TBL] [Abstract][Full Text] [Related]
12. Proliferative activity and p53 expression in primary and recurrent pterygia.
Chowers I; Pe'er J; Zamir E; Livni N; Ilsar M; Frucht-Pery J
Ophthalmology; 2001 May; 108(5):985-8. PubMed ID: 11320032
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of Hsp90 and Ki-67 in pterygium.
Sebastiá R; Ventura MP; Solari HP; Antecka E; Orellana ME; Burnier MN
Diagn Pathol; 2013 Feb; 8():32. PubMed ID: 23432803
[TBL] [Abstract][Full Text] [Related]
14. Expression of bcl-2, p53 and Ki-67 in arsenical skin cancers.
Chang CH; Tsai RK; Chen GS; Yu HS; Chai CY
J Cutan Pathol; 1998 Oct; 25(9):457-62. PubMed ID: 9821074
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD44, PCNA and E-cadherin in pterygium tissues.
Yıldırım H; Turan G; Turan M
Indian J Ophthalmol; 2024 May; 72(Suppl 3):S501-S504. PubMed ID: 38648458
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of c-erbB-2, Bcl-2, p53, p21
Missaoui N; Landolsi H; Mestiri S; Essakly A; Abdessayed N; Hmissa S; Mokni M; Yacoubi MT
Pathol Res Pract; 2019 Mar; 215(3):446-452. PubMed ID: 30558966
[TBL] [Abstract][Full Text] [Related]
17. Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium.
Tan DT; Lim AS; Goh HS; Smith DR
Am J Ophthalmol; 1997 Mar; 123(3):404-5. PubMed ID: 9063255
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma.
Llanos M; Alvarez-Argüelles H; Alemán R; Oramas J; Diaz-Flores L; Batista N
Med Oncol; 2001; 18(1):15-22. PubMed ID: 11778965
[TBL] [Abstract][Full Text] [Related]
19. DNA damage in human pterygium: one-shot multiple targets.
Cimpean AM; Sava MP; Raica M
Mol Vis; 2013; 19():348-56. PubMed ID: 23401662
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical study of bcl-2, p53 and Ki-67 expressions in collecting duct carcinoma of the kidney. Five cases and review of the literature on bcl-2, p53 and Ki-67 expressions in renal cell carcinoma and transitional cell carcinoma.
Suzuki K; Tokue A
Urol Int; 2002; 69(1):57-62. PubMed ID: 12119441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
